We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.04 | 0.04% | 97.38 | 97.91 | 97.07 | 97.75 | 591,237 | 18:48:19 |
From May 2019 to May 2024
By Colin Kellaher
Novartis AG (NOVN.EB, NVS) on Wednesday said the U.S. Food and Drug Administration accepted the company's supplemental biologics license application for Xolair for the treatment of nasal polyps in adults with inadequate response to intranasal corticosteroids.
The Swiss drug make said it expects the agency to make a decision on the indication by the third quarter of 2020.
Novartis said Xolair, if approved, would be the first antibody to help reduce the size of nasal polyps and help improve symptoms through targeting and blocking immunoglobulin E.
Xolair is currently approved in the U.S. to treat of moderate to severe persistent allergic asthma and chronic idiopathic urticaria. Novartis and Roche Holdings AG's (ROG.EB) Genentech unit work together to develop and co-promote Xolair in the U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 11, 2019 06:22 ET (11:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
